Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and solution stability evaluation

1. N. Y. Hasan, M. A. Elkawy, B. E. Elzeany and N. E. Wagieh, Stability indicating methods for the determination of clozapine, J. Pharm. Biomed. Anal. 30 (2002) 35-47; DOI: 10.1016/S0731-7085(02) 00125-5.Search in Google Scholar

2. M. Ackenheil, Clozapine pharmacokinetic investigations and biochemical effects in man, Psychopharmacology 99 (1989) 32-37; DOI: 10.1007/bf00442556.10.1007/BF004425562682731Search in Google Scholar

3. A. A. Ambike, K. Mahadik and A. Paradkar, Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in vitro and in vivo evaluations, Pharm. Res. 22 (2005) 990-998; DOI: 10.1007/ s11095-005-4594-z.Search in Google Scholar

4. M. Kluge, A. Schuld, A. Schacht, H. Himmerich, M. A. Dalal, P. M. Wehmeier, D. Hinze-Selch, T. Kraus, R. W. Dittmann and T. Pollmcher, Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever, Psychoneuroendocrinology 34 (2009) 118-128; DOI: 10.1016/j.psyneuen.2008.08.016.10.1016/j.psyneuen.2008.08.01618835660Search in Google Scholar

5. D. Douroumis, Orally disintegrating dosage forms and taste-masking technologies, Expert Opin. Drug Delivery. 8 (2010) 665-675; DOI: 10.1517/17425247.2011.566553.10.1517/17425247.2011.56655321438776Search in Google Scholar

6. V. Venkateswarlu and K. Manjunath, Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles, J. Control. Release 95 (2004) 627-638; DOI: 10.1016/j.jconrel. 2004.01.005.Search in Google Scholar

7. S. A. Agnihotri and T. M. Aminabhavi, Controlled release of clozapine through chitosan microparticles prepared by a novel method, J. Control. Release 96 (2004) 245-259; DOI: 10.1016/j.jconrel. 2004.01.025.Search in Google Scholar

8. T. Vasconcelos, B. Sarmento and P. Costa, Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs, Drug Discov. Today 12 (2007) 1068-1075; DOI: 10.1016/j. drudis.2007.09.005.Search in Google Scholar

9. O. Almarsson and M. J. Zaworotko, Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?, Chem. Commun. 17 (2004) 1889-1896; DOI: 10.1039/B402150A.10.1039/b402150a15340589Search in Google Scholar

10. K. K. Arora and M. J. Zaworotko, Pharmaceutical co-crystals: A new Opportunity In Pharmaceutical Science for a Long-known but Little Studied Class of Compounds, in Polymorphism in Pharmaceutical Solids (Ed. H. G. Brittain), 2nd ed., Informa Healthcare, London 2009, pp. 281-313.Search in Google Scholar

11. K. J. Crowley and G. Zografi, Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability, J. Pharm. Sci. 91 (2002) 492-507; DOI: 10.1002/jps.10028.10.1002/jps.1002811835208Search in Google Scholar

12. E. Gagniere, D. Mangin, S. Veesler and F. Puel, Co-crystallization in Solution and Scale Up Issues, in Pharmaceutical Salts and Co-crystals (Eds. J. Wouters, L. Quere and D. E. Thurston), 1st ed., Royal Society of Chemistry, London 2011, pp. 188-208.10.1039/9781849733502-00188Search in Google Scholar

13. N. Blagden, M. de Matas, P. T. Gavan and P. York, Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates, Adv. Drug Deliv. Rev. 59 (2007) 617-630; DOI: 10.1016/j.addr.2007.05.011.10.1016/j.addr.2007.05.01117597252Search in Google Scholar

14. K. Lobmann, H. Grohganz, R. Laitinen, C. Strachan and T. Rades, Amino acids as co-amorphous stabilizers for poorly water soluble drugs-Part 1: Preparation, stability and dissolution enhancement, Eur. J. Pharm. Biopharm. 85 (2013) 873-881; DOI: 10.1016/j.ejpb.2013.03.014.10.1016/j.ejpb.2013.03.01423537574Search in Google Scholar

15. Y. Gao, J. Liao, X. Qi and J. Zhang, Coamorphous repaglinide-saccharin with enhanced dissolution, Int. J. Pharm. 450 (2013) 290-295; DOI: 10.1016/j.ij pharm.2013.04.032.Search in Google Scholar

16. A. Shayanfar, H. Ghavimi, H. Hamishekar and A. Jouyban, Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties, J. Pharm. Sci. 16 (2013) 577-587.Search in Google Scholar

17. A. Lemmerer, J. Bernstein, and V. Kahlenberg, Hydrogen bonding patterns of the co-crystal containing the pharmaceutically active ingredient isoniazid and terephthalic acid, J. Chem. Crystallogr. 41 (2011) 991-997; DOI: 10.1007/s10870-011-0031-9.10.1007/s10870-011-0031-9Search in Google Scholar

18. M. A. Elbagerma, H. G. M. Edwards, T. Munshi and I. J. Scowen, Identification of a new co-crystal of salicylic acid and benzamide of pharmaceutical relevance, Anal. Bioanal. Chem. 397 (2010) 137-146; DOI: 10.1007/s00216-009-3375-7.10.1007/s00216-009-3375-720039022Search in Google Scholar

19. B. C. Hancock and M. Parks, What is the true solubility advantage for amorphous pharmaceuticals?, Pharm. Res. 17 (2000) 397-404; DOI: 10.1023/a:1007516718048.10.1023/A:1007516718048Search in Google Scholar

20. S. U. Schilling, C. D. Bruce, N. H. Shah, A.W. Malick and J. W. McGinity, Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets, Int. J. Pharm. 361 (2008) 158-168; DOI: 10.1016/j.ij pharm.2008.05.035.Search in Google Scholar

21. D. R. Weyna, T. Shattock, P. Vishweshwar and M. J. Zaworotko, Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: mechanochemistry vs slow evaporation from solution, Cryst. Growth Des. 9 (2009) 1106-1123; DOI: 10.1021/cg800936d.10.1021/cg800936dSearch in Google Scholar

22. A. Newman, D. Engers, S. Bates, I. Ivanisevic, R. C. Kelly and G. Zografi, Characterization of amorphous API: Polymer mixtures using X-ray powder diffraction, J. Pharm. Sci. 97 (2008) 4840-4856; DOI: 10.1002/jps.21352.10.1002/jps.2135218351626Search in Google Scholar

23. C. Guitton, J. M. Kinowski, R. Aznar and F. O. Bressolle, Determination of clozapine and its major metabolites in human plasma and red blood cells by high-performance liquid chromatography with ultraviolet absorbance detection, J. Chromatogr. 690 (1997) 211-222; DOI: 10.1016/s0378-4347 (96)00362-3.Search in Google Scholar

24. M. Vasanthavada, W-Q. T. Tong, Y. Joshi and M. S. Kislalioglu, Phase behavior of amorphous molecular dispersions II: Role of hydrogen bonding in solid solubility and phase separation kinetics, Pharm. Res. 22 (2005) 440-448; DOI: 10.1007/s11095-004-1882-y.10.1007/s11095-004-1882-y15835750Search in Google Scholar

25. Q. Lu and G. Zografi, Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid and PVP, Pharm. Res. 15 (1998) 1202-1206; DOI: 10.1023/a:1011983606606.10.1023/A:1011983606606Search in Google Scholar

26. H. Bley, B. Fussnegger and R. Bodmeier, Characterization and stability of solid dispersions based on PEG/polymer blends, Int. J. Pharm. 390 (2010) 165-173; DOI: 10.1016/j.ij pharm.2010.01.039.Search in Google Scholar

27. J. E. Patterson, M. B. James, A. H. Forster, R.W. Lancaster, J. M. Butler and T. Rades, Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling, Int. J. Pharm. 336 (2007) 22-34; DOI: 10.1016/j.ij pharm.2006.11.030.Search in Google Scholar